Investigator-Initiated Trials and Studies are independently designed, initiated, and conducted by qualified investigators. JY BioMed may provide investigational product supply, regulatory support, or limited financial assistance, but does not serve as the sponsor. Investigators retain full responsibility for study design, regulatory submissions, execution, and reporting.

​

We are particularly interested in supporting research in:

• Gamma Delta T Cell Therapies — Oncology, infectious diseases, immune modulation

• Dendritic Cell-Based Cancer Vaccines — Solid tumors, immune-related disorders

• Umbilical Cord MSC and Exosome Therapies — Regenerative medicine, aging-related, inflammatory conditions

• Anti-CEACAM6 ADC Programs — Difficult-to-treat solid tumors

​

Proposed projects may include translational research, exploratory clinical trials, biomarker identification, or immune profiling studies.

​

​JY BioMed may provide:

• Investigational product access for research use

• Nonclinical data and regulatory documentation support

• Scientific consultation on study feasibility

• Limited research funding (subject to review)

​

All collaborations are subject to internal scientific review and available resources.

​

Application Process

1. Submit a Preliminary Proposal: Research objective, scientific rationale, study design, resource requirements

2. Scientific Review: Evaluation based on scientific merit, feasibility, and alignment with JY BioMed platforms

3. Final Agreement: Legal and compliance review; execution of collaboration agreement if approved

4. Study Execution and Reporting: Investigator conducts study in accordance with GCP and regulatory standards